Mirum’s EXPAND study tests maralixibat for treatment-resistant cholestatic pruritus
Mirum will reveal LIVMARLI EXPAND Phase 3 results on October 12, testing whether maralixibat can treat itching in additional rare liver diseases.
Pharma & Biotech